ArticleFrontiers in microbiology2018
Colistin Resistant
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Molecular Characterization of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2026Article
- Effect of polymyxin resistance evolution on the fitness costs of Acinetobacter baumannii and the underlying mechanisms of polymyxin resistance.Scientific reports · 2026Article
- Albumin Nanoparticles Improve Colistin Performance Against Hetero- and Full-Resistant ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Lineage-Specific Associations between the Resistome and Mobilome across 10,500 Globally DistributedComputational and structural biotechnology journal · 2026Article
- Mutation- and Transcription-Driven Omic Burden of Daptomycin/Dalbavancin-R and Glycopeptide-RS Fitness Costs in High-Risk MRSA: A Nexus in Antimicrobial Resistance Mechanisms-Genome Proneness-Compensatory Adaptations.Antibiotics (Basel, Switzerland) · 2025Article
- Fitness Burden for the Stepwise Acquisition of First- and Second-Line Antimicrobial Reduced-Susceptibility in High-Risk ESKAPE MRSA Superbugs.Antibiotics (Basel, Switzerland) · 2025Article
- Colistin Resistance Mechanism and Management Strategies of Colistin-ResistantPathogens (Basel, Switzerland) · 2024Review
- TracingMicroorganisms · 2024Article
- Alteration in the Morphological and Transcriptomic Profiles ofMicroorganisms · 2024Article
- Unveiling the Secrets ofInternational journal of molecular sciences · 2024Review
- PmrAB, the two-component system ofJournal of bacteriology · 2024Article
- Genomic investigation unveils colistin resistance mechanism in carbapenem-resistantMicrobiology spectrum · 2024Article
- Role of transcriptomic and genomic analyses in improving the comprehension of cefiderocol activity inmSphere · 2024Article
- Resensitization to colistin results in rapid and stable recovery of adherence, serum resistance and ompW in Acinetobacter baumannii.PloS one · 2024Article
- Structure-based targeting of the lipid A-modifying enzyme PmrC to contrast colistin resistance inFrontiers in microbiology · 2024Article
- Glyoxylate Shunt and Pyruvate-to-Acetoin Shift Are Specific Stress Responses Induced by Colistin and Ceragenin CSA-13 in Enterobacter hormaechei ST89.Microbiology spectrum · 2023Article
- Clonal relatedness of carbapenem-resistant Acinetobacter baumannii: high prevalence of ST136Annals of clinical microbiology and antimicrobials · 2023Article
- Colistin Resistance inAntibiotics (Basel, Switzerland) · 2023Review
- The deficiency of poly-β-1,6-N-acetyl-glucosamine deacetylase trigger A. baumannii to convert to biofilm-independent colistin-tolerant cells.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Even though colistin-based treatment represents the antimicrobial-regimen backbone for the management of multidrug-resistant Gram-negative infections, colistin resistance is still rare, at least as a full resistance, in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.